الفهرس | Only 14 pages are availabe for public view |
Abstract Summary n activation, platelets secrete an array of growth factors that contribute to bone regeneration. Combining plateletrich plasma (PRP) with bone graft substitutes has the potential to reduce or replace the reliance on auto-grafts. Lack of standardization and improper use may contribute to the conflicting outcomes reported within both preclinical and clinical investigations using PRP. This study investigates the effect of PRP dose on bone augmentation. Bone grafting is an essential surgical tool for the augmentation of bone defects; Autogenous bone graft remains the most reliable treatment option due to its ability to provide an osteo-conductive matrix, osteo-inductive factors, and osteogenic properties. However, in addition to the limited supply, the harvesting of auto-graft has been associated with a high rate of complications. Platelets release a variety of signalling molecules that orchestrate bone healing. The basis of platelet-rich plasma (PRP) relies on the ability to concentrate and activate platelets, and to deliver a supra-physiologic concentration of the released growth factors to a defect site. The present study evaluated the efficacy of activated PRP combined with a biphasic calcium phosphate (BCP) to treat established critical-sized cancellous bone defects on bone tumors |